IP Verse

Gip/Glp1 Agonist Compositions

Patent No. EP3810201 (titled "Gip/Glp1 Agonist Compositions") was filed by ELI Lilly on Jun 14, 2019. The application was issued on Aug 2, 2023.

Patent Summary

Pharmaceutical GIP/GLP1 co-agonist peptide composition for subcutaneous injection. The composition comprises tirzepatide, NaCl, and dibasic sodium phosphate. The composition includes tirzepatide, NaCl, and dibasic sodium phosphate.

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BULLE DRMar 7, 2024KUTZENBERGER WOLFF & PARTNER
GALENICUM HEALTH SLUMar 7, 2024GALENICUM HEALTH SLU
GENERICS UKMar 7, 2024ELKINGTON AND FIFE
ELKINGTON AND FIFEMar 6, 2024ELKINGTON AND FIFE
STRAWMANMar 6, 2024HOFFMANN EITLE
KRAUS & LEDERER PARTGMBBMar 5, 2024KRAUS & LEDERER PARTGMBB
SANDOZFeb 23, 2024TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3810201

ELI LILLY
Application Number
EP19739766A
Filing Date
Jun 14, 2019
Status
Granted And Under Opposition
May 5, 2023
Publication Date
Aug 2, 2023
External Links
Slate, Register , Google Patents